COMP <GO>
ENGN vs VYGR // EV/EBITDA & P/E VALUATION
enGene Therapeutics Inc. (NASDAQ) VS. Voyager Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ENGN 2
— VYGR 1
■ METRIC PARITY
LAST: $1.53 (-3.16%) • MKT CAP: $102.5M
valuation
—
LAST: $1.76 (-4.35%) • MKT CAP: $108.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENGN VS. VYGR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENGN | VYGR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -49.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | ENGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 29.5 | +15.01 | ENGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $102.5M | $108.4M | -$5.9M | VYGR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENGN REV | VYGR REV | ENGN GROSS % | VYGR GROSS % | ENGN FCF | VYGR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $40.4M | — | — | -$100.7M | -$135.1M |
| FY 2024 | $0 | $80.0M | — | — | -$49.2M | -$18.8M |
| FY 2023 | $0 | $250.0M | — | — | -$24.7M | $77.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENGN // BETA —
VYGR // BETA —